Available Technologies
# of Displayed Technologies: 1 / 1
Categories
Anti-Retroviral Therapy (Nelfinavir) for NF2-Related Schwannomatosis (NF2) and Other NF2 Deficient Tumors**NOTE: NCH is not pursuing a filing on this due to prior art and inventorship matter**
TS-004606 — For patients with NF2-related Schwannomatosis, there's currently no FDA-approved treatment drug available. Using Nelfinavir, an existing FDA-approved drug, will efficiently and safely block retroviral protease activity. This anti-retroviral drug reduces the growth of existing tumors and prevents/slows the generation of new tumors.
Developing a new drug will cost about $1 billion and take more than 15 years to reach the clinic. But repositioning an existing FDA-approved drug accelerates development and reduces risks and expenses for pharmaceutical companies by using pharmacokinetic and toxicity data on current treatments. Curr…
- College:
- Inventors: Biswas, Pipasha; Meyer, Kathrin
- Licensing Officer: Eidahl, Jocelyn
